Valneva Withdraws Chikungunya Vaccine IXCHIQ Applications In U.S. Amid FDA Suspension

Valneva SE (VALN), a specialty vaccine company, announced that it has voluntarily withdrawn both the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ, in the United States. The decision follows the suspension of the vaccine's license by the U.S. Food and Drug Administration (FDA) in August 2025. Valneva had been awaiting further guidance on its formal response to the suspension but was recently informed that the FDA has placed the IND on ...